- Home
- MSM vs TNGX Comparison
MSM vs TNGX Comparison
Compare MSM & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSM | TNGX |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.1B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MSM | TNGX |
|---|---|---|
| Price | $122.78 | $29.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $96.20 | $21.78 |
| AVG Volume (30 Days) | 809.2K | ★ 6.4M |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $3,363,817,000.00 | $62,384,000.00 |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | $39.39 | ★ N/A |
| Revenue Growth | 4.99 | ★ 48.29 |
| 52 Week Low | $78.80 | $5.34 |
| 52 Week High | $127.51 | $34.39 |
Technical Indicators
Market Signals| Indicator | MSM | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 53.88 |
| Support Level | $82.51 | $27.65 |
| Resistance Level | N/A | $34.39 |
| Average True Range (ATR) | 3.57 | 2.05 |
| MACD | 0.13 | -0.25 |
| Stochastic Oscillator | 64.86 | 26.85 |
Price Performance
Historical ComparisonAbout MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.